Novo takes the plunge in Alzheimer’s

Is Novo Nordisk brave or foolhardy? The company’s decision to take its oral GLP-1 analogue Rybelsus into pivotal trials in Alzheimer’s next year is certainly bold – especially given the recent failure of the Elad trial of the similarly acting Victoza, and a flop this week from VTV Therapeutics, another proponent of the Alzheibetes hypothesis.